Spravato (esketamine) is a medication that has been recently approved by the US Food and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD). TRD is a condition where an individual has not responded to at least two antidepressant treatments. Spravato is a nasal spray that is administered under the supervision of a healthcare professional in a clinic setting.

Spravato works by targeting a different brain chemical, glutamate, compared to traditional antidepressants that target serotonin. It is thought to work by increasing the availability of certain neurotransmitters, such as serotonin and dopamine, that are associated with mood regulation. This unique mechanism of action has led to Spravato being considered a breakthrough treatment for TRD.